FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:680-681 September 8, 1994 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Moertel, C. G. PubMed Citation

To the Editor: We believe that hepatic atrial infusion, new drugs, and biochemical modulation deserve more attention than they received in Dr. Moertel's review of chemotherapy for colorectal cancer (April 21 issue)¹. With respect to hepatic arterial infusion, two large studies with a crossover design demonstrated survival advantages for patients who were crossed over from systemic to hepatic arterial chemotherapy; two studies in which there was no survival advantage associated with hepatic therapy involved only small numbers of patients². In the study by the National Cancer Institute,² the median survival was 22 and 12 months for the groups . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.